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Abstract 
Bahasa Malaysia 
Tajuk: Penilaian pengecutan isipadu fibroid dan rahim selepas "embolisasi" salur darah. 
Tujuan: Tujuan kajian in adalah untuk mengukur peratus pengecutan isipadu fibroid dan 
rahim selepas 'embolisasi'. Kami juga mengkaji apakah komplikasi yang timbul selepas 
penyekatan salur darah rahim dan mengkaji manakah gejala pesakit berkurang selepas 
embolisasi. 
Metodologi: 
Dua bel as ( 12) pesakit telah menjalani penyekatan kedua-dua salur darah rahim bagi 
ketumbuhan fibroid yang bersimtomatik. Kajian in dijalankan selama 21 bulan di Hospital 
Universiti Sains Malaysia. Semua pesakit in telah menjalani pemeriksaan Magnetic 
Resonance Imaging (MRI) sebelum "embolisasi" salur darah rahim tetapi hanya sepuluh 
(10) pesakit mengulangi pemeriksaan MRI tiga bulan selepas "embolisasi" salur darah 
rahim. Seorang pesakit mengalami pendarahan selepas "embolisasi" salur darah rahim dan 
histerektomi telah dilakukan. Seorang lagi pesakit telah hamil sejurus selepas "embolisasi" 
salur darah rahim dan melahirkan seorang bayi perempuan yang sihat melalui pembedahan. 
Isipadu rahim dan isipadu fibroid yang terbesar telah diukur sebelum dan selepas 
"embolisasi". Bandingan isipadu sebelum dan selepas "embolisasi" dibuat untuk mengukur 
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peratus pengecutan. Pemulihan gejala dan komplikasi yang timbul disebabkan oleh 
penyekatan salur darah rahim juga dicatat. 
Keputusan: 
Keputusan menunjukan isipadu fibroid berkurang sebanyak 63.82% dengan interquartle 
range sebanyak 36.78. Isipadu rahim berkurang sebanyak 47.85% dengan interquartile 
range sebanyak 33.96. Pengurangan gejala adalah sebanyak 85-100%. Komplikasi yang 
diperhatikan adalah komplikasi yang ringan dan hanya satu komplikasi yang rumit yang 
memerlukan pembedahan histerektomi. 
Kesimpulan: 
"Embolisasi" salur darah rahim adalah satu cara yang efektif dan selamat untuk merawati 
fibroid. Ia menunjukkan kekurangan gajala pesakit dan isipadu rahim serta fibroid yang 
memuaskan. 
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English 
Title: Assessment of volume reduction of uterus and uterine fibroids using arterial 
embolization 
Objective: The objective ofthis study was to assess the volume reduction ofthe uterus and 
the uterine fibroid using artery embolization for patients with symptomatic fibroids. This 
study was also aimed to determine the complications of uterine artery embolization and to 
document improvement ofthe symptoms post UAE. 
Materials and Methods: Twelve patients had bilateral uterine artery embolization(UAE) 
for symptomatic uterine fibroids. This study was conducted over a period of 21 months in 
Hospital Universiti Sains Malaysia. All the patients had a pre-embolization Magnetic 
Resonance Imaging (MRI) and ten of the patients had a repeat MRI three months post 
uterine artery embolization. One patient developed bleeding post-embolization and had a 
hysterectomy done. The second patient got pregnant immediately post-embolization and 
delivered a healthy term baby girl by caesarean section. Volume of the uterus and the 
dominant fibroid was calculated pre-embolization and post-embolization. Comparison was 
done between the volume pre-embolization and post-embolization, to see the percentage of 
reduction. Symptom improvement and the complication due to uterine artery embolization 
were also noted. 
XI 
Results 
Results show fibroid volume reduction median to be 63.82% with interquartile range of 
36.78 and uterine volume reduction median to be 47.85% with interquartile range of 36.99. 
Symptom improvement at three months was 85-100%. The complications which occurred 
were mostly minor complications with one major complication requiring hysterectomy. 
Conclusion: 
UAE is an effective and a safe method of treatment for symptomatic uterine fibroids. There 
is significant symptom and volume reduction of both the uterus and the dominant fibroid. 
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INTRODUCTION 
1.0 INTRODUCTION 
Uterine artery embolization was initially used in the management of life threatening 
gynaecological bleeding. In 1995, Ravina et al first described the use of uterine artery 
embolization as an alternative treatment of symptomatic uterine fibroids. The basic 
principle of this procedure is intravascular occlusion of the uterine arteries causing hypoxia 
and necrosis of the fibroids. Subsequently the fibroids shrink and there is symptomatic 
relief. Uterine necrosis is avoided since there is adequate collateral circulation. 
In the past twelve years, uterine artery embolization has been gaining increasing 
acceptance as a minimally invasive treatment for symptomatic uterine fibroids. The less 
invasive nature of the procedure, shorter recovery period and preservation of the uterus, 
has made uterine artery embolization a popular alternative to hysterectomies or 
myomectomies. 
Multiple studies have shown that menorrhagia and bulk-related symptoms improve in 80-
97% of patients who undergo uterine artery embolization (Brunereau et a/., 2000, 
Chrisman eta/., 2005, Goodwin eta/., 1999, Ravina eta/., 1995, Spies eta/., 1999, Spies 
eta/., 200 I b, Siskin et a/., 2000a, Worthington-Kirsch et a/., 1998, Worthington-Kirsch et 
a/., 1998). There is also a reduction in volume of the fibroids of between 50% -70% post-
embolization. (mean reduction 45%-55%) (Bum eta/., 1999, Goodwin eta/., 1999, Spies 
eta/., 1999, Ravina et a/., 1995, Pelage et a/., 2000, Siskin et al., 2000a, Worthington-
Kirsch et a/., 1998). However, all the data available and the studies done are from 
developed countries where the quality of care and technology available differs from our 
local set up. Hence there is a need to establish new data applicable to our local population 
and environment. 
UAE does not vary very much from center to center. It has been extensively described in 
many of the studies done and recently in the year 200 I there were guidelines given in the 
Journal of Vascular and Interventional Radiology (JVIR) by the SCVIR. Variation may be 
seen in the technique where some approached the uterine artery directly with a 5F catheter 
or some used microcatheters; some prefer unilateral femoral approach and some prefer 
bilateral approach and the other possible variation is the preference of embolic material. 
Current imaging modality of choice for pre and post-embolization is MRI since it is not 
operator dependent, images are reproducible, signal intensities can somewhat predict the 
outcome of volume reduction and other comorbid disease can be ruled out. Post-
embolization MRI displays the infarcted fibroids clearly and allows the detection of any 
residual enhancing tissue. 
The focus of this study was to determine the volume reduction of the fibroid and the uterus 
post UAE. The short term efficacy and safety of this procedure was also evaluated by 
assessing the symptom relief and the complication rates. Fibroids are the major cause of 
hysterectomies in Malaysia representing 4 7.6% of the indications for surgery (Ravindran 
and Kumaraguruparan, I 998). UAE has been proven to be an alternative treatment which 
when compared to hysterectomies, UAE has a lower morbidity and mortality rates. Pinto et 
al (2003) reported that UAE had a shorter hospital stay and resulted in fewer major 
complications when compared to hysterectomies. 
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To our knowledge there is no published data regarding UAE and the success of UAE in 
treating uterine ftbroids in Malaysia. The purpose of this study was also to provide local 
data and also to start a new service in our hospital. Since UAE is considerably a new 
technique of treating uterine fibroid; it is not well known among our patients and treating 
doctors. This turned out to be our main limitation in acquiring our sample size. We only 
had a total of twelve patients of which one was referred from Terengganu, two were 
referred from Kota Bharu and the rest were from USM. This was despite the introduction 
of this study to the Obstetrics and Gynecology department of the respective hospitals. This 
was done via a presentation to them by us. However referrals were limi ted as the treating 
docLDn preferred to perform hysterec!omies. Referrals were also limited due La the refusal 
by th~ I1Htiet'ltQ fo t• UAH OQ thi9 n1odo of tJ'CGtmmlt i9 gtl ll now In out· countt'Y. Tho 
knowledge regar·d;ng u, ;s PI'OQecii,JJ'e ;s sl;l/1;,, ,; /ecl as we ob~e r·vecl O lll' own tllecl;cAI ~ I A fl~ 
wlto h:we not heard of It Our Imitation of Including pallents who had c;omplctcd th lr 
fam ilies and only includ ing patients with symptomatic fi broids further limited our sample 
size. The other problem faced was the pre-embolization and post-embolization procedural 
MRI which had to be performed. This was because of the cost being very high and also 
had a long waiting list (3 months) for an appoin tment. Discussion regarding our study is 
severely limited due to our small sample size. 
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LITERATURE 
REVIEW 
2.0 LITERATURE REVIEW 
2.1 General Overview 
Uterine fibroids have been a leading caused of hysterectomies all over the world. Up to 
1995 uterine fibroids were either treated medically or surgically. However since 1995, with 
the development of uterine artery embolization (UAE), many extensive studies have been 
done to determine the role of UAE as a viable option. 
2.2 Anatomy 
2.2.1 Vascular anatomy of the uterus 
The uterus is primarily supplied by the uterine arteries which arise from the internal iliac 
arteries (Fig. I). Other than that the uterus is also supplied by the branches of the ovarian 
arteries, vaginal arteries and direct branches of the internal iliac· arteries. It is important to 
know the vascular supply of the uterus as the fibroid may be supplied by any of the above 
branches. 
The fundus of the uterus is supplied by the uterine artery in 90% and by the ovarian artery 
in 1 0% of cases. Vice versa, the ovary is supplied by the ovarian artery alone in 40%, by 
the uterine artery and the ovarian artery in 56% and by the uterine artery alone in 4 % of 
cases (Binkert et a/., 2001 ). The duality of supply of the uterus and the ovaries requires 
angiographic assessment of the vascular supply prior to embolization. 
A dual blood supply also suggests the possibility of anastomosis between the uterine and 
the ovarian arteries. Anastomosis between uterine arteries and ovarian arteries have been 
classified into three groups (Razavi et a!., 2002), Type I, Type II and Type III. In Type I, 
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the ovarian artery supplies the fibroids by way of connections to the intramural uterine 
artery. A subgroup is noted in Type I where, when flow in the tubal artery is low, the 
pressure generated during selective uterine angiography is sufficient to overcome it and 
cause reflux into the ovarian artery (Type Ib ). In Type II, the ovarian artery feeds the 
fibroids directly. In Type III, the ovarian supply appears to be from the uterine artery. 
Evaluations of these anastomoses are important as they affect the final outcome of UAE 
and also to avoid non target embolization. 
The normal ovarian artery which measures less than 1 mm in diameter is usually not 
visualized on a flush aortography. However in a diseased state, the ovarian artery tends to 
get larger. Arteries which are larger than 1.5mm are usually detectable on a flush 
aortography. Binkert et al (2001) reported visualizing an ovarian artery in 25% of patients 
with uterine fibroids in the flush aortography done pre-embolization. The visualization of 
the ovarian arteries in the generally used angiographic technique; where a non selective 
pelvic arteriography is carried out with a catheter placed at the aortic bifurcation and 
followed by direct selective catheterization of the uterine arteries is unlikely. To detect the 
presence of ovarian collateral blood supply, an application of nonselective flush 
arteriography with the tip of the catheter at the level of the renal arteries and imaging 
centered over the pelvis is required. 
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Figure 1 : Vascular anatomy of uterus 
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2.2.2 Classification of fibroids 
Fibroids are divided according to their locations and are grossly classified into submucosal, 
intramural and subserosal (Fig. 2). Subserosal and submucosal fibroids can become 
pedunculated. The subserosa} fibroid can protrude into the pelvic cavity and the 
submucosal fibroid can protrude into the uterine cavity. Pedunculated fibroids can undergo 
torsion and post UAE there can be stalk necrosis. In view of the possibility of stalk 
necrosis, UAE was initially considered unsuitable for pedunculated subserosa! fibroids. 
Goodwin et al (200 1) further classified fibroids as 
1. Pedunculated submucosal: a submucosal fibroid attached by a stalk narrower than 
50% ofthe diameter of the fibroid. 
2. Broad-based submucosal or mixed intramural/submucosal: a broad-based fibroid 
that substantially distorts the endometrial lining of the uterus. 
3. Intramural: fibroid that is centered in the wall ofthe uterus with or without mild to 
moderate distortion of the endometrial or serosal surface. 
4. Transmural: fibroid centered in the myometrium but substantially distorting both the 
endometrial and serosal surfaces of the uterus. 
5. Subserosa): a fibroid centered in the outer myometrium with substantial distortion 
of the serosal surface of the uterus. 
6. Pedunculated Subserosa): subserosa) fibroid with its center outside the uterus 
attached to the uterus by a stalk narrower than 50% of the diameter of the fibroid. 
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Occasionally the subserosal fibroid can detach from the uterus and deposit elsewhere in the 
peritoneal cavity as a parasitic fibroid. 
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Subse«osal 
1ib;oid 
lr tr :~rnur at 'rb10 id 
Sue rnucosal 
fi t: roro 
Pec:ll:ncuiJ :e d 
su os.erosal 'ibroid 
Figure 2 : Classification of fibroids 
Image was downloaded from the following site from the internet on the 06-05-2006. 
mai lto :info@,ask4ufe .com 
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2.3 Uterine Fibroids 
2.3.1 Prevalence 
Leiomyomata, better known as fibroids, are the most common benign tumors of the female 
genital tract, occurring in about 25% of women of childbearing age (Lupattelli eta/., 2005). 
Some literature mention rates as high as 40% in women aged 40 years or older (Tulandi, 
2003). The true prevalence of these tumors has not been truly calculated as many patients 
with these tumors are clinically asymptomatic. Histological examinations of I 00 
consecutive hysterectomy specimens were carried out by Cramer and Patel. They found 
649 leiomyomas in 77 of those specimens, with multiplicity of leiomyomas found in 84% 
of cases (Cramer and Patel, 1990). 
A prospective cross-sectional study involving 14 government hospitals was undertaken 
over a period of 6 months in Malaysia to study the patterns of hysterectomy for 
gynaecological indications. A total of 707 patients were enrolled in the study consisting of 
612 abdominal hysterectomies and 95 vaginal hysterectomies. Fibroids (47.6%) formed the 
main indications for surgery (Ravindran and Kumaraguruparan, 1998). 
2.3.2 Histopathology 
Fibroids are smooth muscle tumors, ansmg from the smooth muscle and the fibrous 
connective tissue of the uterus. Fibroids are generally benign proliferations. However, 
they can undergo malignant transformation into uterine sarcomas. The total incidence of 
uterine sarcomas among patients operated on for uterine leiomyomas, is extremely low and 
a study done showed the incidence to be 0.23% (Parker eta/., 1994). 
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Morphologically, the fibroid is composed of whorled rubbery pink white tissue with no 
true capsule. A fibroid can be calcified, degenerated or cystic. Gross appearance of the 
fibroid can be altered by either haemorrhage, where there will be dark red areas, or by 
necrosis, where we can see sharply demarcated yellow areas. Microscopically, fibroids are 
composed of smooth muscle cells with interspersed fibrous connective tissue. 
Prior to embolization two thirds of all myomas show some degree of degeneration. Three 
most common types of degeneration are hyaline degeneration, myxomatous degeneration 
and calcific degeneration (Stench ever et al., 200 I). 
Immediately post-embolization, the fibroids show thrombosis and necrosis. Thrombosis is 
caused by the embolic material within the vessels. Ultimately, thrombosis results in arterial 
occlusion, leading to interstitial oedema within the fibroid. This is followed by ischemic 
necrosis and later hyaline degeneration (Siskin et al., I999, Lipman et al., 2002). Several 
weeks post-embolization, fibroids show coagulative necrosis and acute inflammatory 
changes. A few months after embolization, fibroids show features of hyaline necrosis and 
dystrophic calcification. Gross morphology post-embolization shows dusky red softening 
in contrast to the characteristic firm, white whorled appearance of a myoma. 
Histologically, foreign body emboli can be seen in blood vessels at the periphery. 
Microscopic examination shows coagulative necrosis characterized by cytoplasmic 
eosinophilia and fragmentation of the nuclei. (Tulandi, 2003) 
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2.3.3 Radiological imaging 
The role of imaging is for the diagnosis of the uterine fibroids, to rule out any other factors 
causing uterine enlargement and to differentiate other possible pelvic masses. MRI is the 
choice imaging modality as it unequivocally demonstrates the myometrial origin of the 
fibroids, where other investigation techniques such as transvaginal ultrasounds, are 
indeterminate. Other imaging modalities include transabdominal ultrasonography, which is 
very much operator dependant and computed tomography which involves radiation to the 
pelvis and ovaries. 
a) MRI of the pelvis. 
MR images depict the uterine zonal anatomy clearly. On T2 weighted images, the central 
zone which includes the endometrium and any fluid in the endometrial cavity, is depicted 
as high signal intensity. Surrounding this there is the junctional zone which is a region of 
low signal intensity. Adjacent to this is the myometrium which is depicted as a region of 
intermediated signal intensity. At the periphery there is a thin hypointense zone observed. 
On Tl weighted or proton density images, the zonal anatomy is poorly differentiated due 
to the isointensity of the uterine zones. 
A fibroid is composed of tightly bound smooth muscle cells and fibrous tissue, which is 
seen as a well defined low signal intensity area on T2 weighted images. On T 1 weighted 
images, the fibroids have intermediate signal intensity; hence there is difficulty in 
distinguishing it from the myometrium. MRI features of fibroids also depend on the 
presence or absence of degenerative changes such as haemorrhagic, hyaline, mucinous, 
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fatty, myxomatous and cystic degeneration. In addition to this the fibroid may also calcify. 
Degenerative changes may account for the increased signal intensity on T2 weighted 
images and T I weighted images may be useful in depicting hemorrhagic degeneration. 
Post-intravenous gadolinium, the enhancement of the fibroid is less in comparison to the 
surrounding myometrium. MRI is also useful to differentiate adenomyosis and 
sarcomatous change of the fibroid prior to the embolization. 
Pre-embolization assessment of the fibroid with a MRI of the pelvis is important for 
assessment of viability of the fibroid, volume pre-embolization, enhancement pattern 
(Nikolaidis et a/., 2005), anatomical location and the vascular supply of the fibroid. 
Assessment of the fibroid post-embolization is best done with MRI where the volume 
reduction of the fibroid (Bum et al., 2000), the significance of signal intensities pre and 
post-embolization, vascularity of the fibroid and changes to the myometrium can be 
assessed. MRI also allows the precise quantitative assessment of the response to therapy 
(Jha eta/., 2000). 
b) Ultrasound (US) of the pelvis 
US of the pelvis can be done either trans abdominal or trans vaginal. It is useful in the 
diagnosis of uterine fibroids and other uterine pathologies. The limitation of US is that it is 
operator dependant and there is difficulty in accurately defining the location of the uterine 
fibroid. 
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c) Computed tomography (CT) of the pelvis. 
CT scan has limited role in the imaging of the uterine fibroids as it involves radiation to the 
pelvic structures and has relatively limited contrast resolution. 
Imaging of the fibroid is important as it is required for confirmation of the diagnosis, for 
selection of patients for appropriate management, to monitor the outcome of the therapy 
and also for follow up. 
2.3.4 Treatment 
Treatment of uterine fibroids for many years was either medical or surgical. Medical 
treatment includes anti-estrogen drugs such as tamoxifen, which is a combination of 
gonadotropin-releasing hormone agonists which often relieve the patient of their symptoms 
temporarily (used only for 3-6 months). Other drugs are progesterone and androgenic 
agents like gestrinone. 
Other options like surgical procedures including myomectomies (which preserves 
reproductive function but recurrence is seen in 25% of the patients), and hysterectomies (a 
radical procedure that is associated with some surgical risks to the patient and results in 
infertility) often are needed later despite the medical treatment. 
The latest treatment option for symptomatic uterine fibroid became available in 1995 when 
Ravina et al used UAE for management of fibroids. The study done was on 16 patients 
with a mean follow up of 20 months. Results showed that there was 20-80o/o volume 
reduction and symptomatic relief was noted. 
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2.4 UAE 
2.4.1 Technique 
a) Pre-embolization assessment 
Patient selection is based on confirmation of the diagnosis and the indication of the UAE. 
Most patients undergoing UAE are patients who wish to preserve their uterus or to avoid a 
surgical procedure. Many of them have either had failed medical or surgical treatment. 
Goodwin et al ( 1999) analyzed possible prognostic factors such as age, race, size, 
vascularity of fibroid and previous medical or surgical therapies. Only age and earlier 
myomectomy were significant prognosticators of the outcome. Co-morbid diseases which 
may also affect the outcome of UAE have to be considered. Studies done in the previous 
years suggested that there is clinical failure after UAE in patients with underlying 
adenomyosis. Other co-morbid factors that have to be considered are ovarian cyst, tubal 
inflammation, endometriosis or diverticulosis. Chances of a life threatening infection are 
increased with chronic salpingitis or endometriosis (Goodwin et a/., 1999, Smith et al., 
1999). 
Pre-embolization imaging should be done to provide information on the type, number and 
size of the fibroids. Pre-embolization MRI is an ideal tool for assessment. In a study done 
by Nikolaidis et al (2005); MRI in 94 patients prior to embolization, showed the 
prevalence of non viable fibroids to be 20% however in approximately two thirds of these 
cases, the non viable fibroids were not dominant. Only 6% were dominant nonviable 
fibroids hence MRI helps in omitting UAE as an option for treatment in these instances. 
15 
MRI imaging also excluded another 16% of patients from proceeding with UAE based on 
the number of fibroids, uterine size, adenomyosis, dominant submucosal fibroids and 
endometrial lesions. Thus MRI imaging can be used to determine the viability of the 
tumors and to detect other findings that preclude UAE. 
Studies done show that large fibroids and pedunculated fibroids are not an absolute contra-
indications for embolization. Katsumori et al evaluated 152 patients of which, 47 patients 
had fibroids larger than I Ocm and the rest had fibroids smaller than I Ocm. They studied the 
possibility of a large fibroid being a high risk for UAE. Complications posts UAE were 
analyzed. There were 30 complications, 25 of which were minor complications. In 
comparison between the two groups, there were no statistical differences noted in the 
complication rates. Hence they concluded that there is no increased risk on the basis of 
tumor size in patients undergoing UAE. The largest tumor embolized was 19cm in 
diameter (Katsumori I et al., 2003). 
Katsumori et al (2005) also reported that UAE can be a safe and effective treatment for 
pedunculated subserosa) fibroids with stalk diameters of 2cm or larger. One hundred and 
ninety six patients consecutive women were studied of which I 2 showed one or more 
pedunculated fibroids. Fifteen pedunculated fibroids were identified. Mean stalk diameter 
before embolization was 3.1 em (range 2.0-5.5cm) and mean tumor volume was 279m I. 
The mean baseline uterine volume was 976ml. Four months post-embolization, MRI was 
performed and showed tumor volume reduction of 41%, and at one year it was 53%. The 
mean stalk diameter was 3.2cm at 4 months and 2.9cm at one year post-embolization. 
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Uterine volume reduction at 4 months was 35% and at I year was 47%. This study has 
excluded patients with a stalk diameter of less than 2cm hence concluding that any 
peduculated subserosa! fibroids with a stalk of more than 2cm have successful outcome 
post-UAE (Katsumori I et al., 2005). 
MRI signal intensity prior to embolization can predict the response to UAE. Multiple 
studies done (Burnet al., 2000, deSouza and Williams, 2002, Jha et al., 2000) reported that 
fibroids which had high signal intensity on Tl weighted images show a poor response to 
UAE. This is because high signal intensity on T1 images indicated hemorrhagic 
degeneration in which the fibroid had outgrown the blood supply, hence the poor response 
to UAE. Fibroids which have high signal intensity on T2 weighted images showed good 
response to UAE. 
b) Embolization 
Embolization techniques have been extensive described in various studies done previously. 
(Goodwin et al., 1999, Pelage et al., 2000, Ravina et al., 1995, Spies et al., 1999, 
Worthington-Kirsch et a!., 1998). The techniques vary from centre to centre but do not 
differ vastly. The basic concept is placement of a catheter into the uterine artery and 
injection of embolic material to occlude the lumen. Subsequently there will be an 
infarction and shrinkage of the fibroid. Technical variation may be in the choice of 
catheters, as some use SF catheters ((Pelage et al., 2000, Worthington-Kirsch et al., 1998) 
to directly cannulate the uterine arteries and some prefer microcatheters (Goodwin et a/., 
I999). 
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c) Embolic material 
The debate regarding the ideal embolic material is still on going. Non spherical polyvinyl 
alcohol (PV A) particles were the first embolic material used successfully for UAE. 
(Goodwin et al., 1999, Ravina et al., 1995, Spies et al., 1999, Worthington-Kirsch et al., 
1998). PV A has limited potential for recanalization and it is a permanent occlusive agent. 
Tris-acryl gelatin microspheres (T AGM), which are spherical embolic particles, have been 
developed and used in France since 1994. By November 2002, tris-acryl gelatin 
microspheres gained popularity as non spherical PV A had the tendency to clump and had 
unpredictable levels of arterial occlusion. However a randomized comparative study done 
by Spies et al in year 2004, to compare PV A and TAGM showed no differences between 
the outcomes ofUAE. The study showed microcatheter occlusion was more common with 
use of PV A and larger volumes of TAGM were used in comparison to PV A (Spies et al., 
2004). 
PV A particles used are of various sizes ranging from 150um-750um. Smaller particles 
cause better devascularization of the fibroids and higher rates of complete resolution of 
symptoms. Larger particles do not cause good devascularization of the fibroid, however the 
risk of uterine infarction and non target embolization is reduced (Lupattelli et al., 2005). 
A recent advancement is the development of spherical PV A in March 2004. A study done 
by Spies et al in year 2005 to compare spherical PV A and T AGM showed unacceptably 
high rates of failed tumor infarction when using spherical PV A. 
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Other embolic materials used are gelatin sponge particles. A study done in 60 patients who 
underwent UAE using gelatin sponge particles successfully showed that the post-
embolization outcome bears comparison with those UAE with PYA as reported in 
literature (Katsumori I et a!., 2002). 
d) Radiation doses 
UAE is performed under fluoroscopic guidance which involves exposure of the gonads to 
ionizing radiation. Nikolic et al (2000) conducted a study using dosimeters which were 
placed in the posterior fornix of the vagina in 20 patients who underwent UAE. The 
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screening times ranged between 9 and 52 min (mean 22 min). The radiation dose of the 
fluoroscopy varied between 2.9 Rlmin (0.75 mc/(kg min)) and 4.4 Rlmin 
(1.13 mc/(kg min)), and 21-62 (mean 44) screenings were performed. The mean estimated 
ovarian dose was 22.34cGy and the mean absorbed skin dose was 162.32cGy. In 
comparison to the pelvic radiation received in treatment of Non Hodgkin's 
lymphoma(absorbed ovarian dose 263-3500cGy), the dose received during UAE is much 
lower than the dose needed to cause any acute or long term injury or increase the genetic 
risk to the patient's future children. 
Nikolic et al (2000) did another study on influence of radiographic technique and 
equipment on absorbed ovarian dose associated with UAE. The absorbed ovarian dose 
during UAE can be reduced by limiting fluoroscopy time and the use of magnified 
fluoroscopy. 
19 
Pron et al (2003) reported procedure time and fluoroscopy time averaged 61 minutes (95 % 
CI; 58-63 minutes) and 18.9 minutes (95 % CI; 18-19.8 minutes). The fluoroscopic time is 
lower than that reported by Nicolic et al (2000). This varied significantly among 
interventional radiologist. There is an average reduction of 27% in procedure time and 24 
% reduction in fluoroscopy time with increasing UAE experience of the interventional 
radiologist. 
The embolization technique for uterine fibroids has been decisively optimized in recent 
years. Screening times range between 14 and 15 min on average. The radiation dose is 
minimized by applying pulsed fluoroscopy, dispensing with magnification factors and 
placing diaphragms. 
2.4.2 Complications 
Complications are divided into those which occur during the procedure (incidence is less 
than I %.) and those that occur after the procedure (Sterling et al., 2002). Complications 
from UAE have been arbitrarily divided into three categories based on the interval from the 
procedure to the onset of the complication: immediate (related to the technical aspects of 
the procedure itself), acute (within 30 days), and long term (after 30 days). Each 
complication has also been categorized as major or minor complications. The rating of the 
severity of each complication was according to the standard definitions of outcome created 
by the Society of Cardiovascular & lnterventional Radiology (SCVIR). 
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a) Complications during the procedure 
Complications that occur during the procedure are arterial catheterization related 
complications such as arteriovenous fistulas, pseudoaneurysms, haematomas, arterial 
thrombosis and infections. 
Haematoma and bleeding from the puncture site requires compression. Sometimes if the 
bleeding is excessive, a transfusion may be required. Pseudoaneurysms if small are treated 
conservatively, and if large may require percutaneous thrombin injections. Arteriovenous 
fistulas and arterial thrombosis may be managed with percutaneous techniques or may 
require open surgical repairs. Infections can be avoided by using aseptic techniques and 
prophylactic antibiotics. 
Other vascular complications include arterial dissection, vasospasm, non target 
embolization and vessel perforation. Arterial dissection is managed conservatively. 
Embolization of the ipsilateral vessel is usually done at a later date; however embolization 
of the contralateral vessel can be attempted. Sometimes embolization on the ipsilateral 
vessel can also be attempted in the same setting if there is still antegrade flow and the true 
lumen is identified. 
Vasospasm can be avoided by using microcatheters however if it still occurs, intra-arterial 
vasodilators such as verapamil and nitroglycerin can be used. During the spasm of the 
vessel, embolization should not be performed as there are high chances of non target 
embolization due to absent antegrade flow. Embolization performed during a vascular 
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spasm has also high chances of failure due to the recanalization of the embolic material 
when the vessel relaxes. 
Non target embolization should be avoided using meticulous technique. Areas most likely 
affected by non target embolization are the pelvic organs and both the lower limbs. 
Management would depend on the severity of the non target embolization. Vessel 
perforations can be managed with coils or gelfoam embolization may be required. Other 
procedural complications include contrast reaction which is managed according to practice 
guidelines. 
b) Post procedural complications 
i) Expulsion of fibroids or large fibroid fragments 
This is a known phenomenon that occurs in patient with submucosal fibroids. Post-
embolization the fibroid is necrotic and sloughs off into the uterine cavity .Fragments are 
usually passed out however in some cases the cervical canal may be obstructed and there 
can be pyometra formation. Patients will present with abdominal pain, fever and raised 
total white count. These patients will require referral to the gynecologists for cervical 
dilatation and removal of the impacted fragments. 
ii) Uterine ischaemia and infarction 
This is a known complication as both the uterine arteries are embolized. However this does 
not occur in most of the patients as there is a rich collateral supply to the uterus. Several 
hours post-embolization the collaterals open up and follow up MRI of the pelvis shows re-
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perfusion post-embolization (Katsumori et a!., 2001). Post-embolization necrosis of the 
fibroid is a sequelae and this can cause the uterine wall to thin out and subsequently 
rupture. Patients having multiple intramural fibroids and still considering on getting 
pregnant post-UAE should be advised of this risk. 
If post-embolization, the patient presents with abdominal pain, raised total white cell count 
and fever, the possibility of uterine ischemia should be considered. MRI is the best 
imaging modality to confirm the diagnosis. There have been case reports where patients 
have presented with uterine ischemia. In the reports uterine ischemia was proven by 
hysterectomy and subsequent histopathology reports (Gabriel et a!., 2004, Godfrey and 
Zbella, 200 I, Torigian et a!., 2005). 
ii) Infection of the necrotic fibroid and /or the uterus 
Patients which present with low grade fever on and off, purulent per vaginal discharge, 
abdominal pain and raised total white counts more than 7 days post UAE should raise the 
suspicion of infection. The infection may involve the uterus or the infarcting fibroid. 
Symptoms may sometimes present as late as three months post procedure hence patients 
have to be followed up closely for three months. Patients presenting with the above 
symptoms have to be investigated with abdominal imaging, cultures and blood counts. 
Imaging evidence of the persistent presence of gas within the myometrium, inflammatory 
changes of the uterus or presence of free fluid surrounding the uterus have to be looked for. 
Prophylactic antibiotic can be given to patients who have higher risk of infection or to all 
patients either pre or post-embolization. There is no consensus regarding the antibiotic 
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cover. No prospective studies have been done to answer the question of need of antibiotic 
cover. 
Spies et al (2002) reported the frequency and severity of complications that occur as a 
result of UAE. The study population was 400 consecutive patients who had UAE. They 
found most of the complications were minor complications, the most common being 
allergic reaction which comprised 21% of all adverse events. There was 64% of a variety 
of other minor complications which did not require hospitalization. The most common 
complication requiring hospitalization was fibroid tissue passage. Thirty four patients 
experienced peri procedural complications at the rate of 8.5% (95% CI 6%-11. 7%) and 
there were 5 major complications (SCVIR class D) comprising of 1.25 % (95% CI 0.3%-
2.5%) of the study population. Using American College of Obstetricians and 
Gynecologists (ACOG) definitions of perioperative complications, the overall morbidity 
was 5% (95% CI 3.1%-7.7%). Findings suggested short term complication rate was low in 
women undergoing UAE. 
Pron et al (2003) reported procedural rate of complication of 5.3% (95% CI 3.6%-7.4%). 
There were 30 adverse events of which only three were major complications requiring 
extended hospital stay or additional care. 
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